SCHEMBL25035485

SCHEMBL25035485

CC(C)n1c(=O)c(-c2ccc(NS(=O)(=O)N(C)C)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.48
ALOX5AP P20292 2/20 0.46
FEN1 P39748 2/20 0.46
MTOR P42345 3/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 2/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
CYP3A4 P08684 1/20 0.37
BRAF P15056 2/20 0.35
GLA P06280 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
RORC P51449 1/20 0.35
RPS6KA3 P51812 1/20 0.35
KIT P10721 2/20 0.35
LMNA P02545 1/20 0.34
PI4KA P42356 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035568 0.86 ERN1 (0.45) ERN1ALOX5APFEN1CYP1A2USP2
SCHEMBL25035427 0.86 BRAF (0.51) ERN1ALOX5APFEN1BRAFRORC
SCHEMBL25035369 0.85 ERN1 (0.57) ERN1ALOX5APFEN1ALDH1A1CYP1A2
SCHEMBL25035335 0.85 ERN1 (0.58) ERN1ALDH1A1CYP1A2HSD17B10USP2
SCHEMBL25035590 0.84 ERN1 (0.47) ERN1ALOX5APFEN1MTORALDH1A1
SCHEMBL25035480 0.84 ALOX5AP (0.48) ERN1ALOX5APFEN1MTORALDH1A1
SCHEMBL25035417 0.84 ERN1 (0.49) ERN1ALOX5APFEN1MTORALDH1A1
SCHEMBL25035656 0.84 ERN1 (0.50) ERN1ALOX5APFEN1MTORALDH1A1
SCHEMBL25035324 0.84 ERN1 (0.50) ERN1ALOX5APFEN1MTORALDH1A1
SCHEMBL25035440 0.83 ERN1 (0.48) ERN1KITPI4KAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD ERN1 3167/4885ALOX5AP 1186/4885FEN1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.